Stoke Therapeutics (STOK) Change in Cash (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly Change in Cash came in at $74.4 million in Q1 2026, down 49.3% year-on-year from $146.8 million in Q1 2025, and up 8911.99% quarter-over-quarter from $826000.0 in Q4 2025.
Stoke Therapeutics (STOK) Change in Cash (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Change in Cash history runs 9 years deep, the most recent figure standing at $74.4 million for Q1 2026.
- On a quarterly basis, Change in Cash fell 49.3% year-over-year to $74.4 million in Q1 2026; TTM through Mar 2026 was -$116.2 million, a 220.5% decrease from a year earlier, with the FY2025 full-year figure at -$43.8 million, up 30.67% from the prior year.
- Change in Cash grew to $74.4 million in Q1 2026 per STOK's latest filing, from $826000.0 in the prior quarter.
- Across five years, Change in Cash topped out at $146.8 million in Q1 2025 and bottomed at -$173.3 million in Q2 2025.
- The 5-year median for Change in Cash is $160000.0 (2022), against an average of $818588.2.
- Across the five-year window, Change in Cash plunged 1986.41% in 2024 and jumped 1241.69% in 2025, its largest moves.
- Year by year, Change in Cash stood at $160000.0 in 2022, then soared by 815.62% to $1.5 million in 2023, then tumbled by 1588.46% to -$21.8 million in 2024, then surged by 103.79% to $826000.0 in 2025, then jumped by 8911.99% to $74.4 million in 2026.
- Per Business Quant, the three latest STOK Change in Cash figures stand at $74.4 million (Q1 2026), $826000.0 (Q4 2025), and -$18.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -22.03 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -2.44 Mn |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn | 243.78 Mn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn | 417.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn | -153.10 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | 74.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.44 Mn |
| Dec 31, 2025 | 826,000.00 |
| Sep 30, 2025 | -18.15 Mn |
| Jun 30, 2025 | -173.35 Mn |
| Mar 31, 2025 | 146.83 Mn |
| Dec 31, 2024 | -21.81 Mn |
| Sep 30, 2024 | -43.46 Mn |
| Jun 30, 2024 | 14.90 Mn |
| Mar 31, 2024 | -12.86 Mn |
| Dec 31, 2023 | 1.47 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | 1.72 Mn |
| Mar 31, 2023 | 76.78 Mn |
| Dec 31, 2022 | 160,000.00 |
| Sep 30, 2022 | 45.64 Mn |
| Jun 30, 2022 | -16.36 Mn |
| Mar 31, 2022 | -60.78 Mn |
| Dec 31, 2021 | -4.29 Mn |
| Sep 30, 2021 | -19.54 Mn |
| Jun 30, 2021 | -98.43 Mn |